• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Reviva Pharmaceuticals Holdings Inc.

    8/23/24 4:07:26 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RVPH alert in real time by email
    SC 13D/A 1 sax20240822_sc13da.htm SCHEDULE 13D/A sax20240822_sc13da.htm

     

     



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 8)*

     

    Reviva Pharmaceuticals Holdings, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    76152G 100

    (CUSIP Number)

     

    Parag Saxena

    Vedanta Management, L.P.

    250 West 55th Street, Ste 13D

    New York, NY 10019

    (212) 710-5220

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    August 22, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     



     

     

     

     

    CUSIP No. 76152G 100

     

    1.

    Names of Reporting Persons.

    Vedanta Associates-R, L.P.

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐ (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

    WC

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     

    6.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    7.

    Sole Voting Power

    0

     

    8.

    Shared Voting Power

    1,958,668

     

    9.

    Sole Dispositive Power

    0

     

    10.

    Shared Dispositive Power

    1,958,668

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,958,668

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    ☐

     

    13.

    Percent of Class Represented by Amount in Row (11)

    5.7%*

     

    14.

    Type of Reporting Person (See Instructions)

    PN

     

     

    *See Item 5 for additional information.

     

     

     

     

    CUSIP No. 76152G 100

     

    1.

    Names of Reporting Persons.

    Vedanta Associates, L.P.

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐ (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

    WC, AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     

    6.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    7.

    Sole Voting Power

    0

     

    8.

    Shared Voting Power

    3,408,401

     

    9.

    Sole Dispositive Power

    0

     

    10.

    Shared Dispositive Power

    3,408,401

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,408,401

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    ☐

     

    13.

    Percent of Class Represented by Amount in Row (11)

    9.5%*

     

    14.

    Type of Reporting Person (See Instructions)

    PN

     

     

    *See Item 5 for additional information.

     

     

     

     

    CUSIP No. 76152G 100

     

    1.

    Names of Reporting Persons.

    Beta Operators Fund, L.P.

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐ (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

    WC

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     

    6.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    7.

    Sole Voting Power

    0

     

    8.

    Shared Voting Power

    2,138,130

     

    9.

    Sole Dispositive Power

    0

     

    10.

    Shared Dispositive Power

    2,138,130

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,138,130

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    ☐

     

    13.

    Percent of Class Represented by Amount in Row (11)

    6.1%*

     

    14.

    Type of Reporting Person (See Instructions)

    PN

     

     

    *See Item 5 for additional information.

     

     

     

     

    CUSIP No. 76152G 100

     

    1.

    Names of Reporting Persons.

    Vedanta Partners, LLC

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐ (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

    AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     

    6.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    7.

    Sole Voting Power

    0

     

    8.

    Shared Voting Power

    5,367,069

     

    9.

    Sole Dispositive Power

    0

     

    10.

    Shared Dispositive Power

    5,367,069

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,367,069

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    ☐

     

    13.

    Percent of Class Represented by Amount in Row (11)

    14.5%*

     

    14.

    Type of Reporting Person (See Instructions)

    OO

     

     

    *See Item 5 for additional information.

     

     

     

     

    CUSIP No. 76152G 100

     

    1.

    Names of Reporting Persons.

    Parag Saxena

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐ (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

    WC, AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     

    6.

    Citizenship or Place of Organization

    India

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    7.

    Sole Voting Power

    884,537

     

    8.

    Shared Voting Power

    5,367,069

     

    9.

    Sole Dispositive Power

    884,537

     

    10.

    Shared Dispositive Power

    5,367,069

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,251,606

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    ☐

     

    13.

    Percent of Class Represented by Amount in Row (11)

    16.9%*

     

    14.

    Type of Reporting Person (See Instructions)

    IN

     

     

    *See Item 5 for additional information.

     

     

     

     

    Explanatory Note

     

    This Amendment No. 8 to Schedule 13D (this “Amendment No. 8”) filed on behalf of Parag Saxena, Vedanta Partners, LLC, Beta Operations Fund, L.P., Vedanta Associates, L.P., and Vedanta Associates-R, L.P. (collectively, the “Reporting Persons”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on September 4, 2018, as amended and supplemented by Amendment No. 1, Amendment No. 2 and Amendment No. 3 on January 19, 2021, Amendment No. 4 on June 3, 2021, Amendment No. 5 on September 12, 2022, Amendment No. 6 on November 30, 2023 and Amendment No. 7 on May 31, 2024 (as amended, the “Schedule 13D”). Except as specifically provided herein, this Amendment No. 8 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

     

    Item 5.

    Interest in Securities of the Issuer

     

    Item 5 of the Schedule 13D is amended and supplemented as follows:

     

     

    (a)

    The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 8 are incorporated by reference into this Item 5. The percentages set forth in row 13 of each cover page are based on 33,093,556 outstanding shares of common stock, par value $0.0001 per share (“Common Stock”), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Issuer”), as of August 22, 2024, as reported directly by the Issuer to the Reporting Persons.

     

     

    (b)

    The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 8 is incorporated by reference. The shares of Common Stock reported as beneficially owned on this Amendment No. 8 consist of the following:

     

    Beneficial Owner

     

    Shares of

    Common

    Stock

       

    Shares

    Underlying

    Warrants

       

    Shares

    Underlying

    Pre-Funded

    Warrants

       

    Shares

    Underlying

    Options

       

    Total

       

    Percentage of

    Outstanding(1)

     

    Vedanta Associates-R

       

    931,000

         

    513,834

    (2)

       

    513,834

         

    0

         

    1,958,668

         

    5.7

    %

    Vedanta Associates(3)

       

    498,539

         

    1,454,931

         

    1,454,931

         

    0

         

    3,408,401

         

    9.5

    %

    Beta Operators

       

    399,000

         

    869,565

    (4)

       

    869,565

         

    0

         

    2,138,130

         

    6.1

    %

    Vedanta Partners(5)

       

    1,429,539

         

    1,968,765

         

    1,968,765

         

    0

         

    5,367,069

         

    14.5

    %

    Parag Saxena(6)

       

    2,300,876

         

    1,968,765

         

    1,968,765

         

    13,200

    (7)

       

    6,251,606

         

    16.9

    %

     

    (1)

    In accordance with Rule 13d-3, the beneficial ownership percentage for each Reporting Person assumes that the warrants and options, if any, held by such Reporting Person have been exercised, and that no other warrants or options have been exercised.

     

     

    (2)

    Excludes 698,250 shares of Common Stock issuable upon the exercise of 931,000 warrants held by Vedanta Associates-R, which contain an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder’s affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates, including the other Reporting Persons) would beneficially own in excess of 4.99% of the shares of Common Stock outstanding immediately after giving effect to the issuance of the shares of Common Stock issuable upon exercise of the warrants (the “Blocker”).

     

     

     

     

    (3)

    The securities beneficially owned by Vedanta Associates consists of securities held directly by Vedanta Associates, Beta Operators and Vedanta R2, including 99,539 shares of Common Stock held directly by Vedanta Associates.

     

     

    (4)

    Excludes 299,250 shares of Common Stock issuable upon the exercise of 399,000 warrants held by Beta Operators, which are subject to the Blocker.

     

     

    (5)

    The securities beneficially owned by Vedanta Partners consists of securities held directly by Vedanta Associates-R, Vedanta Associates, Beta Operators and Vedanta R2.

     

     

    (6)

    The securities beneficially owned by Mr. Saxena consists of securities held directly by Vedanta Associates-R, Vedanta Associates, Beta Operators, and Vedanta R2 as well as 871,337 shares of Common Stock held directly by Mr. Saxena.

     

     

    (7)

    Excludes 8,200 shares of Common Stock underlying options, at an exercise price of $6.04 per share, granted by the Issuer to Mr. Saxena on November 13, 2023 in his capacity as the Chairman of the Board of Directors of the Issuer which are not exercisable within 60 days of the date of this filing.

     

    (c)

    The Reporting Persons have not effected any transactions during the past sixty (60) days from the date of this filing in any securities of the Issuer.

     

     

    (d)

    Except as otherwise reported herein, no person or entity other than the Reporting Persons have the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares of the Common Stock reported on this Schedule 13D.

     

     

    (e)

    Not applicable.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated:

    August 23, 2024

       
     

    VEDANTA ASSOCIATES-R, L.P.

       
     

    By:

    Vedanta Partners, LLC, the general partner of Vedanta Associates-R, L.P.

         
     

    By:

    /s/ Parag Saxena

     

    Name:

    Parag Saxena

     

    Title:

    CEO

       
     

    VEDANTA ASSOCIATES, L.P.

       
     

    By:

    Vedanta Partners, LLC, the general partner of Vedanta Associates, L.P.

         
     

    By:

    /s/ Parag Saxena

     

    Name:

    Parag Saxena

     

    Title:

    CEO

       
     

    BETA OPERATORS FUND, L.P.

       
     

    By:

    Vedanta Associates, L.P., the general partner of Beta Operators Fund, L.P.

         
     

    By:

    Vedanta Partners, LLC, the general partner of Vedanta Associates, L.P.

         
     

    By:

    /s/ Parag Saxena

     

    Name:

    Parag Saxena

     

    Title:

    CEO

       
     

    VEDANTA PARTNERS, LLC

       
     

    By:

    /s/ Parag Saxena

     

    Name:

    Parag Saxena

     

    Title:

    CEO

       
     

    /s/ Parag Saxena

     

    PARAG SAXENA

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

     
    Get the next $RVPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVPH

    DatePrice TargetRatingAnalyst
    9/20/2023$12.00Buy
    ROTH MKM
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    7/26/2021$10.00Buy
    Maxim Group
    More analyst ratings

    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reviva to Participate in the Citizens Life Sciences Conference

      CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY. Citizens Life Sciences Conference Format: Corporate Update / Fireside ChatDate: Thursday, May 8, 2025Time: 10:30 a.m. ETLocation: New York, NYWebcast Link: Click Here About Reviva Reviva is

      4/29/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

      CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ. Details for the poster

      4/24/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

      – Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 – CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2024

      3/31/25 4:05:15 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    SEC Filings

    See more
    • SEC Form S-8 filed by Reviva Pharmaceuticals Holdings Inc.

      S-8 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      4/3/25 7:55:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Reviva Pharmaceuticals Holdings Inc.

      NT 10-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 5:16:54 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 4:12:22 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Financials

    Live finance-specific insights

    See more
    • Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

      - Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and clinically meaningful reductions in all major symptom domains and secondary endpoints at week 4 with 50 mg of brilaroxazine vs. placebo - - Generally well-tolerated with a side effect profile comparable to placebo for the 15 and 50 mg doses of brilaroxazine; discontinuation rates for brilaroxazine lower than placebo - - Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Conference call and webcast

      10/30/23 7:30:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

      9/29/23 9:00:00 AM ET
      $AREC
      $RVPH
      $STSS
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel

      9/22/23 1:30:00 PM ET
      $ARDS
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 5:16:56 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 4:15:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      8/23/24 4:07:26 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

      ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      9/20/23 7:22:47 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target

      The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00

      6/8/23 7:41:12 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Reviva Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $10.00

      1/24/22 6:07:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Narayan Prabhu

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:51 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Bhat Laxminarayan

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:30 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Patel Purav

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      12/12/24 4:35:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care